Transition Bio provides condensate technology for drug discovery and diagnostics.
Transition Bio has raised $13.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2024.
Transition Bio's investors include Bristol-Myers Squibb, Northpond Ventures, Taiho Ventures, Lifeforce Capital, Magnetic Ventures.
Transition Bio is headquartered in Cambridge, United States.
Transition Bio provides condensate technology for drug discovery and diagnostics.
Transition Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Transition Bio — Funding & Investors." VCBacked, October 24, 2024, https://www.vcbacked.co/company/transition-bio. Accessed September 2, 2026.
VCBacked. (2024). Transition Bio — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/transition-bio
{{cite web |title=Transition Bio — Funding & Investors |url=https://www.vcbacked.co/company/transition-bio |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated